Parkinson's disease Nervous System Diseases
Conditions
Interventions
The study design is an ABAB design. 'A' is the placebo gas, 'B' is the hydroxy gas. Each arm will last for two weeks, the study will run for eight weeks in total. Each participant will inhale a hydrox
Sponsors
University of Kent
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. All participants must have a diagnosis of PD by a Neurologist or Geriatrician. 2. All participants must be at stage 2 or stage 3 on the Hoehn and Yahr (H&Y) scale. Stage 1 is too mild and stages 4 and 5 could potentially be too severe for appropriate study participation. 3. Male or female. 4. Able to attend the School of Sport and Exercise Sciences facilities 5. Able to inhale gas for 30 min, twice daily, for a period of 8 weeks 6. Participants' disease state must be stable over the past 2 months
Exclusion criteria
Exclusion criteria: 1. Participants whose Parkinson’s is not controlled. 2. Participants who are at stage 1, stage 4 and stage 5 of the H&Y scale. 3. Participants who cannot consent for themselves.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function and manual dexterity to be measured using a Purdue Pegboard Test (the three-trial administration test-retest will be used to increase reliability) at each visit (at baseline, after 2 weeks of placebo gas inhalation, after 2 weeks of hydroxy gas inhalation, after 2 weeks of placebo gas inhalation, after 2 weeks of hydroxy gas inhalation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measures 1-4 will be assessed at time points of: baseline, after 2 weeks of placebo gas inhalation, after 2 weeks of hydroxy gas inhalation, after 2 weeks of placebo gas inhalation, after 2 weeks of hydroxy gas inhalation. 1.Transient mood measured using a Profile of Mood States (POMS)– Short Form. 2. Visual attention measured using The Flanker Compatibility Task 3. The burden of non-motor symptoms, including non-motor fluctuations, using the Movement Disorder Society Non-Motor Rating Scale 4. Blood markers of oxidative stress, inflammation/neuro inflammation, BDNF will measured in serum or plasma derived from venous blood samples 5. Levels of physical activity measured by an activity tracker worn continuously for eight weeks | — |
Countries
England, United Kingdom
Outcome results
None listed